Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 17,012 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ELEVATE Clear all
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975376
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
545
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 29, 2026, 5:43 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment

NCT06293040
View directory record Official record
Conditions
Cannabis Intoxication, Alcohol Intoxication
Interventions
Cannabis, Alcohol, Placebo Cannabis, Placebo Alcohol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 5:43 AM EDT
Not yet recruiting Not applicable Interventional

Diabetes Prevention by Group Intervention and CGM Use in Pre-diabetic Adults

NCT07543068
View directory record Official record
Conditions
Pre Diabetic, Hyperglycaemia (Non Diabetic)
Interventions
Combines group sessions and CGM-based behavioral feedback
Other
Lead sponsor
Sam Houston State University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Conroe, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 29, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional

Effects of rTMS on Food Choice in Anorexia Nervosa

NCT05918835
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
High-frequency repetitive transcranial magnetic stimulation (active rTMS), Sham repetitive transcranial magnetic stimulation (sham rTMS)
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 29, 2026, 5:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lipid Screening Study

NCT07579325
View directory record Official record
Conditions
Lipoprotein (a)
Interventions
Venipuncture
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 29, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Statin Therapy to Improve Medication Adherence

NCT01894217
View directory record Official record
Conditions
Hypercholesterolemia, HMG COA Reductase Inhibitor Adverse Reaction
Interventions
Genetic testing and reporting for SLCO1B1*5 allele
Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 29, 2026, 5:43 AM EDT
Not yet recruiting Not applicable Interventional

A Social Network Approach to Improve HIV Prevention and Substance Use Treatment For People Who Use Drugs

NCT07409350
View directory record Official record
Conditions
Substance Use, HIV Prevention
Interventions
LINKED, Group Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 29, 2026, 5:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fall Recovery Training for Older Adults in Continuous Care Facilities

NCT02173015
View directory record Official record
Conditions
Accidental Falls
Interventions
Compensatory step training
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 29, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.

NCT04304508
View directory record Official record
Conditions
Acute Non-cardioembolic Ischemic Stroke
Interventions
BAY2433334, BAY2433334 matching placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
1,808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Tampa, Florida • Golden Valley, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 29, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

NCT02615691
View directory record Official record
Conditions
Hemophilia A
Interventions
PEGylated Recombinant Factor VIII, ITI
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 29, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer

NCT00002474
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, cyclophosphamide, mitoxantrone hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support
Drug · Procedure
Lead sponsor
Loyola University
Other
Eligibility
Up to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2005
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 29, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

NCT01995578
View directory record Official record
Conditions
Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML)
Interventions
low dose 5'-azacitidine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 29, 2026, 5:43 AM EDT
Active, not recruiting Early Phase 1 Interventional

Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

NCT01189643
View directory record Official record
Conditions
Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)
Interventions
irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 29 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 29, 2026, 5:43 AM EDT
Not listed Not applicable Interventional

UCLA Breast Cancer Survivor Health Promotion Research Study

NCT05113485
View directory record Official record
Conditions
Breast Cancer
Interventions
Diabetes Prevention Program-based lifestyle change intervention (DPP), Highly Microbiota-Accessible Foods (HMAFs) intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 29, 2026, 5:43 AM EDT
Recruiting Phase 1 Interventional

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

NCT04573140
View directory record Official record
Conditions
Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
Interventions
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Biological
Lead sponsor
University of Florida
Other
Eligibility
4 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 29, 2026, 5:43 AM EDT
Completed No phase listed Observational

Impact of Monthly High Dose Oral Cholecalciferol on Serum 25 Hydroxy Vitamin D Levels in Bariatric Surgery Subjects

NCT01871389
View directory record Official record
Conditions
Bariatric Surgery
Interventions
Not listed
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 29, 2026, 5:43 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

High Confusion: Cannabis & Driving

NCT06236815
View directory record Official record
Conditions
Impairment, Cognitive, Impairment of Attention, Impairment, Psychomotor
Interventions
Delta-9-THC, Delta-8-THC, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 49 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 29, 2026, 5:43 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Prospective Paired Study on the Effectiveness of MitoGrade

NCT02673125
View directory record Official record
Conditions
Infertility
Interventions
MitoGrade
Genetic
Lead sponsor
Reprogenetics
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 29, 2026, 5:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Video Consent Versus Routine Consent for Participation in Research Studies

NCT00430391
View directory record Official record
Conditions
Schizophrenia
Interventions
DVD Consent, Routine Control
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 29, 2026, 5:43 AM EDT
Completed Not applicable Interventional Results available

Multi-Component Prehabilitation for Major Elective Surgery

NCT05752474
View directory record Official record
Conditions
Frailty, Functional Recovery, Prehabilitation
Interventions
Exercise, Nutrition, Meditation, Cognitive Behavioral Intervention
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 29, 2026, 5:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

NCT00788125
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 29, 2026, 5:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

NCT03058289
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
Interventions
INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
Drug · Biological
Lead sponsor
Intensity Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 29, 2026, 5:43 AM EDT
Completed Not applicable Interventional

High Fat Diet II on Weight Loss

NCT00525850
View directory record Official record
Conditions
Obesity
Interventions
high fat diet, low saturated fat diet
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Oct 29, 2026, 5:43 AM EDT
Terminated Phase 1 Interventional

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

NCT01585415
View directory record Official record
Conditions
Metastatic Cancer, Melanoma
Interventions
Vemurafenib, Young TIL, Cyclophosphamide, Fludarabine, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 29, 2026, 5:43 AM EDT